Writing committee: Olivia Keiser, Kathryn Anastos, Mauro Schechter, Eric Balestre, Landon Myer, Andrew Boulle, David Bangsberg, Hapsatou Touré, Paula Braitstein, Eduardo Sprinz, Denis Nash, Mina Hosseinipour, François Dabis, Margaret May, Martin WG Brinkhof, Matthias Egger. Principal Investigators: François Dabis, Matthias Egger, Mauro Schechter. Central Team: Eric Balestre, Martin Brinkhof, Claire Graber, Olivia Keiser, Catherine Seyler, Hapsatou Touré, Charlotte Lewden. Steering Group: Kathryn Anastos (Kigali); David Bangsberg (Mbarara/Kampala); Andrew Boulle (Cape Town); Jennipher Chisanga (Lusaka); Eric Delaporte (Dakar); Diana Dickinson (Gaborone); Ernest Ekong (Lagos); Kamal Marhoum El Filali (Casablanca); Mina Hosseinipour (Lilongwe); Silvester Kimaiyo (Eldoret); Mana Khongphatthanayothin (Bangkok); N Kumarasamy (Chennai); Christian Laurent (Yaounde); Ruedi Luthy (Harare); James McIntyre (Johannesburg); Timothy Meade (Lusaka); Eugene Messou (Abidjan); Denis Nash (New York); Winstone Nyandiko Mokaya (Eldoret); Margaret Pascoe (Harare); Larry Pepper (Mbarara); Papa Salif Sow (Dakar); Sam Phiri (Lilongwe); Mauro Schechter (Rio de Janeiro); John Sidle (Eldoret); Eduardo Sprinz (Porto Alegre); Besigin Tonwe-Gold (Abidjan); Siaka Touré (Abidjan); Stefaan Van der Borght (Amsterdam); Ralf Weigel (Lilongwe); Robin Wood (Cape Town). Advisory Committee: Zackie Achmat, Chris Bailey, Kevin de Cock, Wafaa El-Sadr, Ken Freedberg, Helene Gayle, Charlie Gilks, Catherine Hankins, Tony Harries, Elly Katabira, Jonathan Sterne, Mark Wainberg. Centres which participated in this analysis: CEPREF (Abidjan, Côte d’Ivoire), HIVNAT (Bangkok, Thailand), Hospital de Clinicas/SOBRHIV (Porto Alegre, Brazil), Hospital Universitario Clementino Fraga Filho (Rio de Janeiro, Brazil), ANRS (Dakar, Senegal), Kamuzu Central Hospital/Lighthouse Trust (Lilongwe, Malawi), Generic Antiretroviral Therapy Project AMU (Kampala, Uganda), , Moi University College of Health Sciences/University of Indiana (Eldoret, Kenya), PHRU/Opera (Soweto, South Africa), University of Cape Town/Khayelitsha (Cape Town South Africa), YRG Care (Chennai, India), Immune Suppression Syndrome clinic (Mbarara, Uganda)/Helen Joseph Hospital Themba Lethu Clinic (WITS) (Johannesburg, South Africa), MTCT-Plus/, Mailman School of Public Health/Columbia University (New York, USA), Prospective Evaluation in the Use and Monitoring of Antiretrovirals in Argentina (PUMA) (Buenos Aires, Argentina).
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America
Article first published online: 27 MAR 2008
© 2008 Blackwell Publishing Ltd
Tropical Medicine & International Health
Volume 13, Issue 7, pages 870–879, July 2008
How to Cite
The ART-LINC Collaboration of the International Databases to Evaluate AIDS (IeDEA) (2008), Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Tropical Medicine & International Health, 13: 870–879. doi: 10.1111/j.1365-3156.2008.02078.x
- Issue published online: 27 MAR 2008
- Article first published online: 27 MAR 2008
- 2004) Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 35, 383–392. , , et al. (
- 2006) National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 20, 1497–1502. , , et al. (
- 2006) Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. South African Medicne Journal 96, 315–320. , , et al. (
- 2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817–824. , , et al. (
- 2008) Gender and the use of potent antiretroviral treatment in resource-constrained settings: Findings from a multi-centre collaboration. Journal of Women’s Health 17, 47–55. , , et al. (
- 2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887–895. , , et al. (
- 2000) Missing men’s messages: does the reproductive health approach respond to men’s sexual health needs? Cult Health Sex 2, 135–150. & (
- 2005) Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology 34, 979–986. , , et al. (
- 2003) Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS 17(Suppl. 3), S5–S15. , , et al. (
- 2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119–29. , , et al. (
- 2005) Antiretroviral therapy in resource-poor settings: scaling up inequalities? International Journal of Epidemiology 34, 509–512. , , et al. (
- 2005) AIDS-related stigma in sub-Saharan Africa: its contexts and potential intervention strategies. AIDS Public Policy Journal 20, 25–39. , , et al. (
- 2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367, 1335–1342. , , et al. (
- 2004) Role of gender in health disparity: the South Asian context. British Medical Journal 328, 823–826. & (
- 2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505–510. , , et al. (
- 2003) When HIV-prevention messages and gender norms clash: the impact of domestic violence on women’s HIV risk in slums of Chennai, India. AIDS Behavior 7, 263–272. , , et al. (
- 2000) Men, Masculinities & Development: Broadening Our Work Towards Gender Equality. Gender in Development Monograph Series No. 10. UNDP, Geneva. & (
- 2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases 41, 217–224. , & (
- 2005) Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 19, 2050–2052. , , et al. (
- 2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clinical Infectious Diseases 43, 770–776. , , et al. (
- 2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Tropical Medicine and International Health 12, 929–935. , , et al. (
- 2008) Mortality of HIV-1 infected patients starting antiretroviral therapy (ART) in sub-Saharan Africa: the IeDEA Prognostic Model 15th Conference on Retroviruses and Opportunistic Infections. Boston. Available at: http://www.retroconference.org/2008 (accessed 17 March 2008). , , et al. (
- 2003) Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 17, 815–819. , , et al. (
- Ministry of Health (2004) Health Surveillance Secretariat. National STD/AIDS Programme. Recommendations on Antiretroviral Therapy in HIV-infected Adults and Adolescents. MoH, Brasília.
- 1999) Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 13, 943–950. , , et al. (
- 1998) Anemia and survival in HIV infection. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 19, 29–33. , & et al. (
- 2005) Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reproduction and Health Matters 13, 136–146. , , et al. (
- 2007) Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment. PLoS Medicine 4, e305. , , et al. (
- 1994) Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). Journal of Acquired Immune Deficiency Syndrome 7, 287–295. , , et al. (
- Sociedad Argentina de Infectiologia (2006) Recomendaciones Sobre Tratamiento Antiretroviral. Actualización SADI. SAI, Buenos Aires.
- 1998) Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 91, 301–308. , , et al. (
- 2005) Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. Journal of Acquired Immune Deficiency Syndrome 40, 324–328. , , et al. (
- 2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. Journal of Acquired Immune Deficiency Syndrome 45, 52–59. , , et al. (
- UNAIDS (2006) Report on the Global AIDS Epidemic. Joint United Nations Programme on AIDS, Geneva.
- 2001) The forgotten fifty per cent: a review of sexual and reproductive health research and programs focused on boys and young men in sub-Saharan Africa. African Journal of Reproduction and Health 5, 175–195. (
- World Health Organization (2002) Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach. WHO, Geneva.
- World Health Organization (2004) Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2003 Revision . WHO, Geneva.
- World Health Organization (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. WHO, Geneva.
- World Health Organization, UNAIDS, UNICEF (2007) Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report, April 2007. WHO, Geneva.
- 2005) Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine 6, 216–223. & (